In Business news

Follow this topic

Bookmark

Record learning outcomes

The family-owned group Jardines Pharmacy has seen post-tax profits grow 57 per cent year-on-year despite sustained pressure on NHS reimbursement, its latest accounts reveal. 

Published in March, the 2024-25 Companies House filing for the Jardines Group – which includes several other companies, such as healthcare device manufacturer P3 Medical – show it made a post-tax profit of £1.9m in the year to March 30, 2025. 

This compares with a £1.2m profit in the 2023-24 financial year, which represented a 60 per cent drop against the £4.8m made by Jardines in 2022-23. 

Turnover rose by 20 per cent to £58.6m, while the cost of sales rose by 22 per cent to £44m, making for a gross profit of £15m in 2024-25 compared to £13m the year before. 

The chain’s operating profit also saw a healthy increase, rising from £1.6m to £2.3m. 

In their financial report, Jardines Pharmacy’s directors say they are “satisfied with the group’s results for the year,” which are set against “a backdrop of unprecedented financial strain on the sector”.

They added: “NHS funding remained stagnant in nominal terms for the ninth year running, meaning cost inflation continued to apply margin pressure. 

“The directors welcome the increase in NHS funding to community pharmacies from April 2025 as a step in the right direction. 

“However, the envelope remains well short of what the sector requires.”

The company’s directors said they are “concerned that the uplift will be swiftly wiped out with ongoing increases to operating costs,” adding that “it remains unknown what will be delivered in future contracts”.

The company’s website currently lists 47 branches, primarily clustered in Milton Keynes and Bedfordshire.